B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4⁺T cell cytotoxicity through ESM1.

ABSTRACT: Immunotherapy exhibited potential effects for advanced hepatocellular carcinoma, unfortunately, the clinical benefits are often countered by cancer adaptive immune suppressive response. Uncovering the mechanism how cancer cells evade immune surveillance would help to develop new immunotherapy approaches and combination therapy. In this article, by analyzing the transcriptional factors which modulate the differentially expressed genes between T cell infiltration high group and low group, we identified oncoprotein B cell lymphoma 6 (BCL6) suppresses the infiltration and activation of tumor infiltrating T lymphocytes, thus correlated with poorer clinical outcome. By using antibody deletion experiment, we further demonstrated that CD4⁺T cells but not CD8⁺T cells are the m

SUBMITTER: Li J 

PROVIDER: S-EPMC11220024 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature